Health Care · Pharmaceutical Preparations

ALT Altimmune, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1326190166 filings
Russell 2000

ALT at a glance

Altimmune, Inc. (ALT, SEC CIK 1326190) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Altimmune, Inc. (ALT) reported revenue of $41,000 (up 105.0% from FY2024) and a net loss of $88.1 million. Diluted EPS was -$1.00.
  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Altimmune, Inc. (ALT) shares worth $200.1 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by MENZIUSO RICHARD THOMAS on November 18, 2026 of 10,000 shares at $1.42 per share.
  • In the last 90 days, ALT insiders reported 4 open-market purchases ($96K) and 0 open-market sales ($0) on Form 4, a net purchase of $96K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$41K
+105.0% vs prior year
Insiders · 90 days
4 buys · 0 sells
Net +$96K
13F holders
29 funds
$200.1M · +1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $0, down 100% YoY from $5,000
  • Net loss $31.6M vs $19.0M YoY, operating loss $35.7M vs $20.9M
  • Best-performing line: MASH R&D $10.7M, up $6.9M YoY; AUD R&D $1.9M, down $1.4M
  • Cash used in operations $82.9M, investments $451.0M at September 30, 2026
  • April offering raised $211.1M net; management expects funding for at least twelve months, with tariff and inflation risks ahead

Risk Factors

  • No material changes from the March 6, 2026 Form 10-K risk factors

AI summary of the ALT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, cash position, operating expenses and pipeline updates

Item EX-99.1: Item EX-99.1

  • Cash, equivalents and investments $480M as of September 30, 2026, supporting continued late-stage clinical development
  • PERFORMA Phase 3 MASH trial advancing, with 52-week topline data expected in 2029
Filed Oct 29, 2026Full analysis →

Item 2.03: Creation of a Direct Financial Obligation

  • $10.0M Tranche Three draw under $125.0M Hercules Capital loan facility
  • Funding tied to achievement of clinical and financial milestones, signaling continued lender support
Filed Oct 27, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expands from nine to eleven directors, adding Peter Greenleaf and Alex Howarth effective November 2, 2026
  • Greenleaf brings former CEO and biopharmaceutical commercial leadership experience, strengthening strategic and industry oversight

Item EX-99.1: Item EX-99.1

  • Peter Greenleaf and Alex Howarth join the board November 2, 2026, adding late-stage development, commercialization, licensing and M&A expertise
  • Three current directors retire at the 2027 annual meeting, marking planned board succession during Altimmune’s transition toward commercialization

Item 7.01: Regulation FD Disclosure

  • Press release announces new Board appointments, signaling a change in governance and potential strategic oversight
  • Exhibit 99.1 contains appointment details, including director identities and effective terms

AI summaries of ALT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ALT

Don't miss the next ALT filing

  • Alerts as it files. A push when ALT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ALT, by share count.
  • Ask anything. An AI agent that reads every ALT filing and answers with sources.

ALT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
MENZIUSO RICHARD THOMASBuyNov 18, 2026$1.42
Durso Jerome BenedictBuyNov 13, 2026$1.62
Pisano WayneBuyNov 13, 2026$1.64
WEAVER GREGORY LBuyNov 13, 2026$1.62
WEAVER GREGORY LMNov 11, 2026-
WEAVER GREGORY LMNov 11, 2026-
WEAVER GREGORY LFNov 11, 2026$1.93
Greenleaf PeterANov 2, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$20K$41K
Operating Income-$95.9M-$103.2M-$94.5M
Net Income-$88.4M-$95.1M-$88.1M
Op. Margin--515860.0%-230461.0%
Net Margin--475295.0%-214861.0%
Balance Sheet
Total Assets$210.6M$139.3M$279.9M
Equity-$123.5M$224.9M
ROE--77.0%-39.2%
Per Share
EPS$-1.66$-1.34$-1.00
Cash Flow
Operating CF-$75.8M-$79.8M-$67.5M
CapEx--$11K

Source: XBRL data in Altimmune, Inc. (ALT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ALT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ALT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$200.1M
Q2 202628$218.1M
Q1 202627$138.0M
Q4 202525$127.0M
Q3 202524$97.3M
Q2 202525$81.6M
Q1 202523$77.2M
Q4 202420$129.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ALT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
4Nov 4, 2026--
4Nov 4, 2026--
8-KOct 29, 2026Analysis-
8-KOct 27, 2026Analysis-
4Oct 5, 2026--
4Oct 5, 2026--
4Oct 2, 2026--
8-KSep 29, 2026Analysis-
4Sep 17, 2026--
4Aug 13, 2026--
8-KAug 12, 2026Analysis-
10-QAug 12, 2026Analysis
4Aug 3, 2026--
4Aug 3, 2026--
8-KJul 28, 2026Analysis-
8-KJun 16, 2026Analysis-
10-QMay 13, 2026Analysis
8-KMay 13, 2026Analysis

Related Health Care companies

All Health Care →

ALT SEC filings: frequently asked questions

Are ALT insiders buying or selling?

In the last 90 days, Altimmune, Inc. (ALT) officers, directors and 10% owners reported 4 open-market purchases worth $96,431 by 4 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ALT stock?

As of September 30, 2026, the largest Altimmune, Inc. (ALT) holders among the 13F filers tracked by SignalX were BlackRock ($59.9 million), State Street Corp ($23.9 million), Vanguard Portfolio Management LLC ($23.2 million), Vanguard Capital Management LLC ($22.3 million), Viking Global Investors ($19.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ALT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Altimmune, Inc. (ALT) reported revenue of $41,000 (up 105.0% from FY2024) and a net loss of $88.1 million. Diluted EPS was -$1.00. The figures come from the XBRL data in the 10-K.

What did ALT report in its latest 8-K?

Altimmune, Inc. (ALT) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest ALT SEC filings?

Altimmune, Inc. (ALT) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 18, 2026.

What is ALT's SEC CIK number?

Altimmune, Inc. (ALT)'s SEC Central Index Key (CIK) is 1326190. EDGAR lists every ALT filing under that number.

Ask anything about ALT

The research agent reads ALT's filings, financials, insider trades and 13F holders, then answers with sources.